Atul Pande bought stock once, on Aug 13, 2021

Atul Pande, MD is a director at Immunovant, Inc. (IMVT), where he has served on the board of directors since October 2019 and contributes deep expertise in clinical development across multiple therapeutic areas.( A psychiatrist by training, he completed his research fellowship in psychiatry at the University of Michigan Medical School and his postgraduate specialty training and residency in psychiatry at Western University.( At Immunovant, a clinical-stage biopharmaceutical company focused on therapies for autoimmune diseases, Dr. Pande provides strategic guidance on drug development and portfolio strategy as a non‑executive/independent director.(

Dr. Pande is currently a board member of Karuna Therapeutics, Autifony Therapeutics, Perception Neurosciences, and Pangea Botanica, and previously served on the board of Sio Gene Therapies.( His executive career includes roles as Chief Medical Officer of PureTech Health and Tal Medical, President/Chief Executive Officer of Verity BioConsulting, and Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline, following senior R&D positions at Pfizer, Parke‑Davis/Warner‑Lambert, and Lilly Research Laboratories.( Over more than two decades in industry, he has been involved in the development and regulatory approval of multiple CNS and other therapeutics, and has served on scientific advisory boards for companies such as Cennerv Pharma and Centrexion Corporation.(

Written by Perplexity from public sources.